Raj. HC: No Jurisdiction on DRT to Modify Settlement Terms in Appli. Filed after Disposal of Matter  ||  Kar. HC: Second Petition u/s 482 of CrPC Not Maintainable Unless Founded Upon Change in Circumstance  ||  Centre to Delhi HC: In Process of Framing Rules Under New Online Gaming Act  ||  Karnataka HC: Compelling DNA Tests without Imminent Need becomes Violative of Article 21  ||  SC: TET Qualification Mandatory for Teachers in Minority Institutions  ||  SC: Agreement to Sell Does Not Confer a Valid Title on a Party as it is Not a Deed of Conveyance  ||  SC Criticizes NGT for Outsourcing its Responsibilities to External Committees  ||  SC: No Culprit Should Manage an Acquittal on the Basis of Unreasonable Doubts  ||  Delhi High Court Dismisses Bail Pleas of Umar Khalid and Other Accused in 2020 Delhi Riots Case  ||  Supreme Court Judges Launch Schemes for Human -Wildlife Conflict    

U.S. PTO Rules in Favour of Mylan - (29 Aug 2016)

U.S.Patent and Trademark Office (PTO) has ruled in the favour of Natco Pharma’s marketing partner Mylan, with regard to patent claims pertaining to multiple sclerosis drug Copaxone.

Tags : U.S.PATENT AND TRADEMARK OFFICE   NATCO PHARMA   PATENT CLAIMS  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved